Precigen, Inc. (NASDAQ:PGEN – Get Free Report) has received an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.00.
A number of brokerages have issued reports on PGEN. HC Wainwright restated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th.
View Our Latest Research Report on Precigen
Institutional Investors Weigh In On Precigen
Precigen Trading Up 3.4 %
NASDAQ:PGEN opened at $1.80 on Tuesday. The company has a market capitalization of $527.16 million, a P/E ratio of -3.27 and a beta of 1.57. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17. The business’s 50-day moving average is $1.55 and its 200 day moving average is $1.13.
About Precigen
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Further Reading
- Five stocks we like better than Precigen
- Top Stocks Investing in 5G Technology
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Pros And Cons Of Monthly Dividend Stocks
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Best Stocks Under $10.00
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.